Shiv K. Singh
Goettingen, NI 37075, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer.
Journal: Cell reports
Published: April 27, 2026
Tumor-intrinsic dichotomy shapes cellular heterogeneity in pancreatic cancer.
Journal: Trends in cancer
Published: October 27, 2025
Expression of gemcitabine metabolizing enzymes and stromal components reveal complexities of preclinical pancreatic cancer models for therapeutic testing.
Journal: Neoplasia (New York, N.Y.)
Published: March 08, 2024
Spatial tumor immune heterogeneity facilitates subtype co-existence and therapy response in pancreatic cancer.
Journal: Nature communications
Published: December 14, 2023
Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.
Journal: Frontiers in immunology
Published: October 17, 2023
RBFOX2: a key factor in suppressing PDAC metastasis through regulation of alternative splicing events.
Journal: Signal transduction and targeted therapy
Published: May 23, 2023
An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies.
Journal: Gastroenterology
Published: February 13, 2023
Mechanisms of PDAC subtype heterogeneity and therapy response.
Journal: Trends in cancer
Published: June 27, 2022
TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer.
Journal: Cancers
Published: June 09, 2022
NFATc1 Is a Central Mediator of EGFR-Induced ARID1A Chromatin Dissociation During Acinar Cell Reprogramming.
Journal: Cellular and molecular gastroenterology and hepatology
Published: May 23, 2022
Last Updated: 09/26/2026